Amyndas’ compound AMY-101 has completed the following clinical trials:
- The First-In-Human Clinical Study of the C3 Complement Inhibitor AMY- 101 in Healthy Male Volunteers:
- A Phase 2a Clinical Trial to Assess the Safety and Efficacy of C3 Inhibitor AMY-101, in Adults with gingivitis:
- COVID-19: A Clinical Trial to Assess the Safety and Efficacy of C3 Inhibitor, AMY-101, in patients with Acute Respiratory Distress Syndrome (ARDS) due to SARS-CoV-2 infection.
- There are no current or planned future clinical trials.